Wall Street Zen Upgrades Grace Therapeutics to Hold Rating

Grace Therapeutics (NASDAQ: GRCE) received an upgrade to a “hold” rating from Wall Street Zen, as detailed in a research report published on October 6, 2023. This change in rating comes amid a mixed outlook for the company’s stock, which has also faced scrutiny from other analysts.

In a contrasting view, Weiss Ratings reaffirmed a “sell (d-)” rating for Grace Therapeutics on October 8, 2023. The divergence in analyst opinions highlights the uncertainty surrounding the stock’s performance. Currently, two analysts have assigned a Buy rating, while one has issued a Sell rating. According to data from MarketBeat.com, the average rating for Grace Therapeutics remains at “Hold,” with an average price target set at $12.00.

Recent Financial Performance and Forecasts

Grace Therapeutics recently disclosed its quarterly earnings on November 13, 2023. The company reported an earnings per share (EPS) of ($0.15), falling short of analysts’ expectations, which had forecast an EPS of ($0.12). This miss by $0.03 raises concerns about the company’s ability to meet financial targets.

Looking ahead, analysts predict that Grace Therapeutics will record an EPS of ($1.06) for the current fiscal year. The anticipated losses reflect the challenges the company faces in achieving profitability amid its ongoing development efforts.

Institutional Investment Activity

Recent changes in institutional holdings indicate varying levels of confidence among investors. Several institutional investors and hedge funds have adjusted their stakes in Grace Therapeutics. For instance, Stratos Wealth Partners LTD. established a new position during the fourth quarter, valued at approximately $39,000. Similarly, SeaCrest Wealth Management LLC acquired a new stake worth about $42,000 in the third quarter.

Other notable investments include Millington Financial Advisors LLC, which took a new position valued at $59,000, and Palumbo Wealth Management LLC, which invested $144,000. Additionally, ADAR1 Capital Management LLC significantly increased its stake by 98.4% in the third quarter, now owning 350,450 shares worth approximately $1,043,000 after acquiring an additional 173,823 shares.

Currently, institutional investors and hedge funds hold 6.08% of Grace Therapeutics’ stock, indicating a cautious but engaged interest in the company’s future prospects.

About Grace Therapeutics

Grace Therapeutics, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative therapies for rare genetic diseases. Leveraging a proprietary platform that combines advanced molecular biology with biologic engineering, the company aims to identify and optimize gene-based and protein-based candidates that target specific genetic drivers of disease.

The company’s pipeline includes multiple preclinical programs aimed at addressing lysosomal storage disorders and other inherited metabolic conditions. As Grace Therapeutics continues its research and development efforts, stakeholders will be closely monitoring its financial performance and strategic direction.

For ongoing updates and insights on Grace Therapeutics and other companies, interested parties can subscribe to MarketBeat.com’s daily email newsletter.